A detailed history of Arizona State Retirement System transactions in Immunovant, Inc. stock. As of the latest transaction made, Arizona State Retirement System holds 14,733 shares of IMVT stock, worth $405,304. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,733
Previous 14,235 3.5%
Holding current value
$405,304
Previous $375,000 8.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$27.51 - $27.51 $13,699 - $13,699
498 Added 3.5%
14,733 $405,000
Q2 2024

Aug 05, 2024

BUY
$25.1 - $31.61 $8,032 - $10,115
320 Added 2.3%
14,235 $375,000
Q1 2024

May 07, 2024

SELL
$30.27 - $43.79 $6,447 - $9,327
-213 Reduced 1.51%
13,915 $449,000
Q4 2023

Jan 24, 2024

SELL
$31.31 - $44.19 $81,406 - $114,894
-2,600 Reduced 15.54%
14,128 $595,000
Q3 2023

Nov 06, 2023

BUY
$18.55 - $39.96 $38,862 - $83,716
2,095 Added 14.32%
16,728 $642,000
Q2 2023

Aug 01, 2023

BUY
$14.2 - $23.75 $48,336 - $80,845
3,404 Added 30.31%
14,633 $277,000
Q1 2023

Apr 27, 2023

BUY
$15.27 - $19.72 $4,626 - $5,975
303 Added 2.77%
11,229 $174,000
Q4 2022

Feb 07, 2023

SELL
$6.59 - $17.75 $955 - $2,573
-145 Reduced 1.31%
10,926 $193,000
Q3 2022

Nov 07, 2022

BUY
$3.93 - $6.37 $121 - $197
31 Added 0.28%
11,071 $62,000
Q2 2022

Jul 28, 2022

BUY
$3.38 - $5.65 $540 - $904
160 Added 1.47%
11,040 $43,000
Q1 2022

May 04, 2022

BUY
$5.06 - $8.77 $237 - $412
47 Added 0.43%
10,880 $60,000
Q4 2021

Feb 04, 2022

BUY
$7.33 - $9.32 $79,405 - $100,963
10,833 New
10,833 $92,000
Q1 2021

May 06, 2021

SELL
$13.08 - $49.6 $130,093 - $493,321
-9,946 Closed
0 $0
Q4 2020

Jan 28, 2021

BUY
$36.36 - $52.71 $2,617 - $3,795
72 Added 0.73%
9,946 $459,000
Q3 2020

Nov 05, 2020

BUY
$22.61 - $38.9 $223,251 - $384,098
9,874 New
9,874 $347,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Arizona State Retirement System Portfolio

Follow Arizona State Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arizona State Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on Arizona State Retirement System with notifications on news.